Fundraising Fox
Renasant Bio
Berkeley, US · Founded 2022 · Delaware corporation · 35 employees on LinkedIn · 5 known investors
Find your way into Renasant Bio
Sign up to see every warm intro you have to Renasant Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Renasant Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.
Founders & leadership
Renasant Bio was founded in 2022 by Jeremy Reiter and Markus Delling.
Board
Investors · 5
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · press coverage · Not right? Tell us
How we know: OrbiMed's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$55.5M disclosed across 2 rounds · 2024–2025
▶$25.5MraisedJul 2025 · 3 investors · BiotechnologyRule 506(b)
- Emily ConleyExecutive Officer, Director
- Deborah PalestrantDirector
- Evan CaplanDirector
- Thomas GustafsonExecutive Officer
- Kevin BittermanDirector
- June LeeDirector
- Offering amount
- $25.5M
- Amount sold
- $25.5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$30MraisedJul 2025 · 4 investors · BiotechnologyRule 506(b)
- Evan CaplanDirector
- Natalie HollesDirector
- Charlotte McKeeDirector
- Deborah PalestrantDirector
- Thomas GustafsonExecutive Officer
- Anna FrenchDirector
- Kevin BittermanDirector
- Emily ConleyExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Renasant Bio went on to found or lead other companies.
Related companies · 6
Companies working in the same space as Renasant Bio.
In the news
Frequently asked questions
- What does Renasant Bio do?
- Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.
- Who founded Renasant Bio?
- Renasant Bio was founded by Jeremy Reiter, Markus Delling in 2022.
- Who are Renasant Bio's investors?
- Renasant Bio's investors include 5AM Ventures, OrbiMed, Atlas Venture, Qiming Venture Partners, Qiming Venture Partners USA.
- How much funding has Renasant Bio raised?
- Renasant Bio has disclosed $55.5M raised across 2 rounds.
- Where is Renasant Bio headquartered?
- Renasant Bio is headquartered in Berkeley, US.